1. Home
  2. SKIN vs RZLT Comparison

SKIN vs RZLT Comparison

Compare SKIN & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Beauty Health Company

SKIN

The Beauty Health Company

HOLD

Current Price

$1.55

Market Cap

179.8M

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$3.24

Market Cap

187.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKIN
RZLT
Founded
1997
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.8M
187.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SKIN
RZLT
Price
$1.55
$3.24
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$2.00
$9.14
AVG Volume (30 Days)
347.1K
6.0M
Earning Date
03-11-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$301,917,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$1.07
52 Week High
$2.69
$11.46

Technical Indicators

Market Signals
Indicator
SKIN
RZLT
Relative Strength Index (RSI) 56.06 47.27
Support Level $1.41 $2.69
Resistance Level $1.65 $2.92
Average True Range (ATR) 0.08 0.27
MACD 0.01 0.33
Stochastic Oscillator 67.27 98.91

Price Performance

Historical Comparison
SKIN
RZLT

About SKIN The Beauty Health Company

The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: